Identifying biomarkers to improve cancer treatment with cryoablation and immunotherapy
Biomarker Identification to Increase Adjunctive Cryoablation and Checkpoint-Inhibitor Immunotherapy Response
This study is looking at how freezing cancer cells with cryoablation, along with a special type of immunotherapy, can help improve treatment for cancer patients, and it aims to find out which patients might benefit the most from this combined approach.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10916209 on NIH RePORTER |
What this research studies
This research investigates how combining cryoablation, a technique that freezes cancer cells, with checkpoint inhibitor immunotherapy can enhance treatment responses in cancer patients. The study aims to identify specific biomarkers that can predict which patients will benefit from this combination therapy. By analyzing tumor samples and immune responses, researchers hope to understand the mechanisms behind improved outcomes. Patients may have their tumors treated with cryoablation to stimulate a stronger immune response against cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are undergoing or considering checkpoint inhibitor therapy and may be eligible for cryoablation.
Not a fit: Patients with tumors that are not amenable to cryoablation or those who are not receiving checkpoint inhibitor therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments by identifying which patients are most likely to benefit from combined therapies.
How similar studies have performed: While the combination of cryoablation and checkpoint inhibitors is minimally studied, there is promising preclinical evidence suggesting potential benefits.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Wehrenberg-Klee, Eric — Massachusetts General Hospital
- Study coordinator: Wehrenberg-Klee, Eric
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.